GMAB News

Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully diluted valuation of $3.6 billion. Medallia’s growth accelerated to 32% in the most recent quarter, and it boasts 32...read more

Genmab, which is developing novel antibodies for cancer and other diseases, raised $506 million in its US IPO by offering 28.5 million ADSs at $17.75, slightly below the as-converted last close of its shares on the Nasdaq Copenhagen and at the time of its launch ($18.11). The company maintained its more than $500 million deal size by selling an additional 700,000 ADSs.  ...read more

July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent tech unicorns, Medallia (MDLA) may get the most eyeballs. DouYu (DOYU) is set to...read more

Genmab, which is developing novel antibodies for cancer and other diseases, announced terms for its IPO on Tuesday. The Copenhagen, Denmark-based company plans to raise $503 million by offering 27.8 million ADSs at a price of $18.11, the as-converted closing price of its shares on the Nasdaq Copenhagen on July 5, where it has been listed since 2000 (GEN). At $18.11 per ADS,...read more